About Us

Indication BioScience will begin by licensing the first of our Statin+ drug concepts, Atorva+. Based on traditional benchmarking methods, we expect initial payment sufficient to pay a significant dividend to investors, and to fund further development. The next major steps post-revenue will include further development of additional Statin+ drugs and the full build-out of the biosynthesis capability. The biosynthesis platform will not only discover next generation drugs, but also develop valuable production technology. Indication BioScience also expects through the course of work in biosynthesis to create proprietary technologies valuable in the production of API, and license these to manufacturers.

Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering pharmaceuticals, and are among the most widely prescribed class of drugs. Statins have been found to reduce cardiovascular disease and mortality in those who are at high risk, but also are associated with unwanted side effects. Indication BioScience has pioneered a new formulation platform for statins, Statin+ that increases effectiveness while decreasing side effects.